Related Experiment Video
Updated: Jul 6, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Rune Sundset1, Hege Sagstuen Haugnes2, Alexander Perez3
1PET-senteret, Universitetssykehuset Nord-Norge, og, Nukleærmedisinsk og strålebiologisk forskningsgruppe, UiT - Norges arktiske universitet.
Background:
Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.
Case Presentation:
A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.
Interpretation:
Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
